Cancer Vaccines

Excerpt from Custom Post Type Indication: CVAC

Oncology Momentum: Tracking the Early Pipeline from AACR to ASCO – Transcript

AACR 2026: Beyond the Abstracts: Webinar

Executive Summary: ONCrg’s PhD analysts review the most significant early-stage oncology developments from AACR 2026 and preview key data expected at ASCO, covering cell therapies, antibody-drug conjugates (ADCs), immuno-oncology, and the DNA damage response (DDR) space.

AACR 2026: Beyond the Abstracts

Oncology Resource Group goes beyond the abstracts to discuss what really happened at AACR 2026.

Emerging Clinical Signals

Excerpt from Custom Post Type Indication: ECS

Antibody Drug Conjugates

Medical Conference Coverage EHA: June 11-14, 2026 WCLC: September 12-15, 2026 ESMO: October 23-27, 2026 SNO: November 12-15, 2026 SABCS: December 8-11, 2026 ASH: December 12-15, 2026  ASCO GU: February 11-13, 2027 ELCC: March 17-20, 2027 SGO: March 19-22, 2027 AACR: April 2-7, 2027 ASCO: June 4-8, 2027 ICML: June 15-19, 2027 Antibody-Drug Conjugates (ADCs) […]

DNA Damage Response

The DNA damage response (DDR) field has seen major advances in recent years, particularly in ovarian, breast, prostate, and pancreatic cancers. Most cancers depend on DNA damage detection and repair for survival and are thus vulnerable to targeted inhibition of DDR proteins. DDR therapies include inhibitors of PARP, ATR, WEE1, and DNA-PK. The DDR field […]

Multiple Myeloma

Excerpt from Custom Post Type Indication: MM

Myelodysplastic Syndromes

Excerpt from Custom Post Type Indication: MDS

Cell Therapies

Excerpt from Custom Post Type Indication: Cell Therapies